Horizon Therapeutics Public Ltd Co
HZNPDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492426
Horizon Therapeutics Public Ltd Co was delisted in 2023; its insiders filed their last Form 4 on Oct 6, 2023; 483 institutions reported holding it in 13F filings for Q3 2023, worth $25.1B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 483
- Q3 2023, −31 vs. previous quarter
- 13F value
- $24.8B
- Reported value at the end of Q3 2023
- Superinvestors holding
- 1
- At the end of Q3 2023
Superinvestors holding HZNP, Q3 2023
1 superinvestor reports holding Horizon Therapeutics Public Ltd Co on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
7.8%
Horizon Therapeutics Public Ltd Co's share of the portfolio
- Shares
- 3,289,584
- Value
- $380.6M
Latest insider trades
Open-market purchases and sales by Horizon Therapeutics Public Ltd Co insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 18, 2023 (view filing) | Jan 17 | 1 day | Pasternak AndyEVP, Chief Strategy Officer | SSale | −27.1K | $113.03 | −$3.07M | −32.5%56.3K after | |
| Jan 17, 2023 (view filing) | Jan 13 | 4 days | Cox AaronEVP, Chief Financial Officer | SSale | −36.1K | $113.17 | −$4.09M | −99.2%277 after | |
| Jan 12, 2023 (view filing) | Jan 10-11 | 2 days | Sherman Jeffrey WEVP and Chief Medical Officer | SSale | −6.74K | $113.08 | −$761.7K | −15.7%36.2K after | 2 lots |
| Jan 6, 2023 (view filing) | Jan 6 | Same day | Sherman Jeffrey WEVP and Chief Medical Officer | SSale | −5.19K | $113.29 | −$587.6K | −9.5%49.3K after | |
| Dec 14, 2022 (view filing) | Dec 13 | 1 day | Pasternak AndyEVP, Chief Strategy Officer | SSale | −30.2K | $112.61 | −$3.40M | −47.0%34.0K after | 2 lots |
| Dec 13, 2022 (view filing) | Dec 12 | 1 day | Sherman Jeffrey WEVP and Chief Medical Officer | SSale | −28.4K | $111.45 | −$3.16M | −25.1%84.4K after | 2 lots |
| Aug 8, 2022 (view filing) | Aug 4 | 4 days | Clayton Sean M.EVP, General Counsel | PPurchase | +745 | $66.67 | +$49.7K | New position745 after | |
| Jul 29, 2022 (view filing) | Jul 29 | Same day | Pasternak AndyEVP and Chief Business Officer | SSale | −4.85K | $82.57 | −$400.5K | −12.5%34.0K after | 2 lots |
| Jul 20, 2022 (view filing) | Jul 19-20 | 1 day | Thompson Elizabeth H.Z.EVP, Research & Development | SSale | −6.01K | $85.00 | −$510.6K | −46.3%6.97K after | 3 lots |
| Jul 11, 2022 (view filing) | Jul 7 | 4 days | Thompson Elizabeth H.Z.EVP, Research & Development | SSale | −82 | $85.01 | −$6.97K | −0.6%13.0K after |
Top 10 13F holders, Q3 2023
The largest institutional positions in Horizon Therapeutics Public Ltd Co at the end of Q3 2023; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 21,587,441 | $2.50B | 0.06% | +42,917+0.2% | Added |
| Pentwater Capital Management LP | 15,552,000 | $1.80B | 17.32% | +2,825,100+22.2% | Added |
| BlackRock Inc. | 14,871,176 | $1.72B | 0.05% | −32,505−0.2% | Reduced |
| HBK Investments L P | 7,978,967 | $923.1M | 20.48% | +1,928,967+31.9% | Added |
| UBS Oconnor LLC | 7,664,245 | $886.7M | 15.86% | +3,332,978+77.0% | Added |
| Norges Bank | 7,105,064 | $822.0M | 0.17% | +1,547,758+27.9% | Added |
| Avoro Capital Advisors LLC | 7,000,000 | $809.8M | 12.63% | 00.0% | Unchanged |
| Farallon Capital Management, L.L.C. | 6,656,823 | $770.1M | 4.35% | −265,000−3.8% | Reduced |
| State Street Corp | 5,233,927 | $605.5M | 0.03% | −40,125−0.8% | Reduced |
| JPMorgan Chase & Co | 5,042,293 | $583.3M | 0.07% | −448,947−8.2% | Reduced |